Carina L. Gehlert

Kiel, SH, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Combination of Fc-Protein Engineering Strategies: Design and Evaluation of Antibody Effector Functions.

Combination of Fc-Protein Engineering Strategies: Design and Evaluation of Antibody Effector Functions.

Journal: Methods in molecular biology (Clifton, N.J.)

Published: May 13, 2026

Myeloid cell-mediated killing of B-ALL by CD38 and CD20 IgA antibody variants is enhanced by CD47/SIRPα interference.

Myeloid cell-mediated killing of B-ALL by CD38 and CD20 IgA antibody variants is enhanced by CD47/SIRPα interference.

Journal: Blood neoplasia

Published: September 24, 2025

Complementary efficacy of CD127-directed immunotherapy with lusvertikimab and ABL-targeting tyrosine kinase inhibitors in preclinical ABL-class-fusion-positive B-ALL.

Complementary efficacy of CD127-directed immunotherapy with lusvertikimab and ABL-targeting tyrosine kinase inhibitors in preclinical ABL-class-fusion-positive B-ALL.

Journal: HemaSphere

Published: September 09, 2025

CD20 expression regulates CD37 levels in B-cell lymphoma - implications for immunotherapies.

CD20 expression regulates CD37 levels in B-cell lymphoma - implications for immunotherapies.

Journal: Oncoimmunology

Published: June 07, 2024

Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers.

Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers.

Journal: mAbs

Published: February 19, 2024

Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells.

Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells.

Journal: Frontiers in immunology

Published: March 03, 2023

Dual Fc optimization to increase the cytotoxic activity of a CD19-targeting antibody.

Dual Fc optimization to increase the cytotoxic activity of a CD19-targeting antibody.

Journal: Frontiers in immunology

Published: May 31, 2022

Identification of New Antibodies Targeting Malignant Plasma Cells for Immunotherapy by Next-Generation Sequencing-Assisted Phage Display.

Identification of New Antibodies Targeting Malignant Plasma Cells for Immunotherapy by Next-Generation Sequencing-Assisted Phage Display.

Journal: Frontiers in immunology

Published: March 30, 2022

Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosis.

Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosis.

Journal: Blood advances

Published: February 18, 2022

Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL.

Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL.

Journal: Blood

Published: October 18, 2021

Multifunctional NK Cell-Engaging Antibodies Targeting EGFR and NKp30 Elicit Efficient Tumor Cell Killing and Proinflammatory Cytokine Release.

Multifunctional NK Cell-Engaging Antibodies Targeting EGFR and NKp30 Elicit Efficient Tumor Cell Killing and Proinflammatory Cytokine Release.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: October 08, 2021

Engineering of CD19 Antibodies: A CD19-TRAIL Fusion Construct Specifically Induces Apoptosis in B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Cells In Vivo.

Engineering of CD19 Antibodies: A CD19-TRAIL Fusion Construct Specifically Induces Apoptosis in B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Cells In Vivo.

Journal: Journal of clinical medicine

Published: April 30, 2021

Showing 1-12 of 14

Last Updated: 09/26/2026